These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 9271330)

  • 1. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NQ-Y15 inhibits the calcium mobilization by elevation of cyclic AMP in rat platelets.
    Chang TS; Lee KS; Lee GY; Jeon SD; So DS; Khil LY; Chung MK; Moon CK
    Biol Pharm Bull; 2001 May; 24(5):480-3. PubMed ID: 11379764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization.
    Jin YR; Cho MR; Ryu CK; Chung JH; Yuk DY; Hong JT; Lee KS; Lee JJ; Lee MY; Lim Y; Yun YP
    J Pharmacol Exp Ther; 2005 Jan; 312(1):214-9. PubMed ID: 15328379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HA-29: an inhibitor of thromboxane A2 formation with antagonism of thromboxane A2/prostaglandin endoperoxide receptor in rabbit platelets.
    Lin CH; Kuo SC; Huang LJ; Huang TF; Teng CM
    Thromb Res; 1992 Apr; 66(1):61-73. PubMed ID: 1412184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism for antiplatelet effect of onion: AA release inhibition, thromboxane A(2)synthase inhibition and TXA(2)/PGH(2)receptor blockade.
    Moon CH; Jung YS; Kim MH; Lee SH; Baik EJ; Park SW
    Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):277-83. PubMed ID: 10883058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
    J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
    Heylen L; De Clerck F; Somers Y; Leysen JE
    Blood Coagul Fibrinolysis; 1991 Oct; 2(5):617-21. PubMed ID: 1838285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet activity of BRX-018, (6aS,cis)-malonic acid 3-acetoxy-6a9-bis-(2-methoxycarbonyl-acetoxy)-6,6a,7,11b-tetrahydro-indeno[2,1-c]chromen-10-yl ester methylester.
    Lee GY; Chang TS; Lee KS; Khil LY; Kim D; Chung JH; Kim YC; Lee BH; Moon CH; Moon CK
    Thromb Res; 2005; 115(4):309-18. PubMed ID: 15668191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
    Ohkubo S; Nakahata N; Ohizumi Y
    Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R; Mezzasoma AM; Venditti G; Gresele P
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
    de Chaffoy de Courcelles D; De Clerck F
    Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Halogen-substituted trimetoquinol analogs as thromboxane A2 receptor antagonists in platelets and aorta.
    Romstedt KJ; Shin Y; Shams G; Doyle K; Tantishaiyakul V; Clark MT; Adejare A; Hamada A; Miller DD; Feller DR
    Biochem Pharmacol; 1993 Dec; 46(11):2051-9. PubMed ID: 8267653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
    Tubaro E; Belogi L; Mezzadri CM
    Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.